10X Genomics Inc is primarily active in the life sciences industry.

The main competitors of 10X Genomics Inc in the market include other innovative biotechnology companies such as Illumina, Pacific Biosciences, and Bio-Rad Laboratories.

10X Genomics Inc is a biotechnology company headquartered in Pleasanton, California. It was founded in 2012 by Serge Saxonov, Benjamin Hindson, and Kevin Ness with a vision to revolutionize genomics research. The company develops and commercializes innovative solutions that enable scientists to study genetic information at unprecedented resolution and scale. By employing its patented technology, 10X Genomics has empowered researchers across multiple disciplines to make groundbreaking discoveries in areas such as cancer research, drug discovery, and immunology. With a strong focus on innovation, 10X Genomics continues to shape the future of genomics research, ensuring its position as a leading player in the field.

10X Genomics Inc has achieved several significant milestones in its development. The company successfully launched its groundbreaking Chromium System, a single-cell analysis platform that enables researchers to analyze cellular heterogeneity at unprecedented resolution. This technological breakthrough has revolutionized genomics research and allowed scientists to gain invaluable insights into complex biological systems. Additionally, 10X Genomics Inc has made remarkable strides in expanding its product portfolio, continuously introducing innovative solutions that empower researchers with cutting-edge genomic tools. Furthermore, the company has established strong partnerships and collaborations with leading academic institutions and pharmaceutical companies, further validating 10X Genomics Inc's expertise and impact in the genomics field.

10X Genomics Inc is primarily present in the United States.

10X Genomics Inc represents a commitment to advancing scientific research and discovery. Their corporate philosophy emphasizes innovation, collaboration, and integrity. The company aims to empower researchers with cutting-edge tools and technologies to unlock new insights in genomics. By offering solutions that enable single-cell and spatial genomics analysis, 10X Genomics Inc plays a vital role in accelerating knowledge in biology and medicine. Their dedication to quality and customer satisfaction has established them as a leader in the field, making 10X Genomics Inc a trusted name in genomics research and a driving force for scientific progress.

Analysts currently set an average price target of 18,43 USD for the 10X Genomics stock (median: 18,36 USD), implying −67,1 % versus the latest price. The consensus is based on 21 analyst ratings.

10X Genomics Analyytikkojen kursstavoitteet 2026

21 analysts currently rate the 10X Genomics stock: 7 recommend buying, 14 holding and 0 selling. For 2026, analysts expect 10X Genomics to generate revenue of 619,43 M USD and earnings per share of 0,03 USD.

10X Genomics Analyytikkojen kursstavoitteet 2026

Converted at the current exchange rate, the 10X Genomics share trades at 48,50 EUR (56,09 USD).

The 10X Genomics share (TXG) is listed on 5 stock exchanges, including: NASDAQ (TXG), Frankfurt (1KJ.F), München (1KJ.MU), Düsseldorf (1KJ.DU), London (0A88.L).

The company 10X Genomics Inc. is a leading provider of genomics technologies and solutions. Its business model is focused on providing innovative tools and products to scientists, researchers, and other customers to improve the understanding of cell biology and genomics. 10X Genomics' main division is the production of single-cell genomics products. The company has developed a unique platform that allows researchers to study individual cells and collect genetic information from them. This platform offers higher resolution than previous technologies that relied on samples from multiple cells, which obscured the misunderstood heterogeneity of cell populations. Numerous differences occurring in cells can be uncovered, allowing scientists to gain new insights into biological processes. 10X Genomics also offers solutions for genome sequencing and has developed a revolutionary technology called Linked-Reads. With this technology, researchers can sequence regions of the genome that were previously inaccessible, leading to important discoveries. Linking specific regions in the DNA helps researchers study large genomic areas more quickly and identify complex structures such as chromosomal variations or gene fusion events. Additionally, 10X Genomics has a growing presence in the market for clinical applications of genomics technologies. The company is currently collaborating with several partners to develop tests and diagnostic tools for early cancer detection, among other future uses. 10X Genomics' business model is based on the development and manufacture of innovative products and technologies, as well as collaboration with customers to create tailored solutions and sell them with added value. The company has experienced rapid growth in the past and values continuous improvement and development of its products and services. In the future, 10X Genomics plans to continue working on new technologies and solutions while expanding and strengthening its existing customer base by closely collaborating with customers in research and clinical diagnostics. The company is demonstrating to the industry how analyzing individual cells in genomics can enable scientists to explore biological complexity in new, deeper ways.

odotettu liikevaihto 10X Genomics on 619,43 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto 10X Genomics on 3,80 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

10X Genomics:n hinta-voitto-suhde (P/E) on tällä hetkellä 1 877,47. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan 10X Genomics-osakkeen arvostusta.

10X Genomics:n hinta-myynti-suhde (P/S) on tällä hetkellä 11,51. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii 10X Genomics-osakkeen arvostuskennuslukuna.

10X Genomics:n Eulpool-laatuscore on 3/10.

10X Genomics:n ISIN on US88025U1097. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

10X Genomics:n WKN on A2PPQJ. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

10X Genomics:n ticker on TXG. Tämä pörssinoteeraus käytetään 10X Genomics-osakkeiden kauppaan pörssissä.

10X Genomics maksoi osinkoa joka vuosi viimeisten 0 vuoden aikana.

10X Genomics kuuluu sektoriin 'Terveydenhuolto'.

10X Genomics:n osingot jaetaan valuutassa USD.